557 related articles for article (PubMed ID: 30193748)
1. Health Care Resource Use, Costs, and Diagnosis Patterns in Patients With Schizophrenia and Bipolar Disorder: Real-world Evidence From US Claims Databases.
Broder MS; Greene M; Chang E; Hartry A; Touya M; Munday J; Yan T
Clin Ther; 2018 Oct; 40(10):1670-1682. PubMed ID: 30193748
[TBL] [Abstract][Full Text] [Related]
2. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
[TBL] [Abstract][Full Text] [Related]
3. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data.
Munday J; Greene M; Chang E; Hartry A; Yan T; Broder MS
Curr Med Res Opin; 2019 Jul; 35(7):1231-1239. PubMed ID: 30649965
[No Abstract] [Full Text] [Related]
4. Health care resource utilization and costs in a commercially insured population of patients with bipolar disorder type I and frequent psychiatric interventions.
Bagalman E; Muser E; Choi JC; Durden E; Macfadden W; Haskins JT; Dirani R
Clin Ther; 2011 Oct; 33(10):1381-1390.e4. PubMed ID: 22000656
[TBL] [Abstract][Full Text] [Related]
5. Healthcare cost, service use and mortality in major psychiatric disorders in Taiwan.
Pan YJ; Kuo KH; Yeh LL
J Affect Disord; 2019 Mar; 246():112-120. PubMed ID: 30580196
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder.
Broder MS; Greene M; Chang E; Hartry A; Yan T; Yermilov I
J Med Econ; 2019 Jan; 22(1):63-70. PubMed ID: 30376745
[TBL] [Abstract][Full Text] [Related]
7. Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia.
Carroll B; Irwin DE
J Manag Care Spec Pharm; 2019 Jul; 25(7):810-816. PubMed ID: 31232207
[TBL] [Abstract][Full Text] [Related]
8. Costs associated with attempted suicide among individuals with bipolar disorder.
Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
[TBL] [Abstract][Full Text] [Related]
9. Treatment costs related to bipolar disorder and comorbid conditions among Medicaid patients with bipolar disorder.
Guo JJ; Keck PE; Li H; Patel NC
Psychiatr Serv; 2007 Aug; 58(8):1073-8. PubMed ID: 17664518
[TBL] [Abstract][Full Text] [Related]
10. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
11. Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study.
Degli Esposti L; Sangiorgi D; Mencacci C; Spina E; Pasina C; Alacqua M; la Tour F
BMC Psychiatry; 2014 Oct; 14():282. PubMed ID: 25312446
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
Kearney M; Thokagevistk K; Boutmy E; Bharmal M
J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
[TBL] [Abstract][Full Text] [Related]
14. Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims Data.
Yermilov I; Greene M; Chang E; Hartry A; Yan T; Broder MS
Adv Ther; 2018 Dec; 35(12):2138-2151. PubMed ID: 30456519
[TBL] [Abstract][Full Text] [Related]
15. Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data.
Marvel J; Vlahiotis A; Sainski-Nguyen A; Willson T; Kimball A
BMJ Open; 2019 Sep; 9(9):e030579. PubMed ID: 31575575
[TBL] [Abstract][Full Text] [Related]
16. Increased health care costs associated with new persistent opioid use after major surgery in opioid-naive patients.
Brummett CM; Evans-Shields J; England C; Kong AM; Lew CR; Henriques C; Zimmerman NM; Sun EC
J Manag Care Spec Pharm; 2021 Jun; 27(6):760-771. PubMed ID: 33624534
[No Abstract] [Full Text] [Related]
17. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.
Bickston SJ; Waters HC; Dabbous O; Tang BI; Rahman M
J Manag Care Pharm; 2008 May; 14(4):352-62. PubMed ID: 18500913
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.
Locklear JC; Alemayehu B; Brody RS; Chavoshi S; Tunceli O; Kern D; Earley WR
Clin Ther; 2013 Dec; 35(12):1923-32. PubMed ID: 24275622
[TBL] [Abstract][Full Text] [Related]
19. Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders.
Ayyagari R; Thomason D; Mu F; Philbin M; Carroll B
J Med Econ; 2020 Feb; 23(2):204-212. PubMed ID: 31663802
[No Abstract] [Full Text] [Related]
20. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
